Drug data last refreshed 7h ago · AI intelligence enriched 1mo ago
VENTOLIN is an oral tablet small-molecule product approved by GSK in 1986 for an undisclosed indication. The specific mechanism of action and therapeutic class are not documented in available data, limiting clinical characterization.
Product is nearing loss of exclusivity; commercial team is likely focused on lifecycle management, cost containment, and competitive defense rather than growth initiatives.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Study Evaluating the Effect of Inhaled PT007(AS MDI) Versus Placebo MDI and Ventolin Evohaler on Lung Function in Adult Participants With Asthma
Green (Sustainable) VENTOLIN - Pharmacokinetics (PK) Study in Healthy Participants
A Study to Assess the Systemic Exposure of FLIXOTIDE™ (Fluticasone Propionate) and SERETIDE™ (Fluticasone Propionate and Salmeterol) Given With VENTOLIN™ Mini-Spacer Compared to the Aerochamber Plus Spacer
A Study to Evaluate the Efficacy and Safety of Meptin® Swinghaler® and Ventolin® MDI in Stable Asthma Patients
Worked on VENTOLIN at GSK? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
No linked job openings currently exist for this product, reflecting its mature, declining stage. Career opportunities are limited to retention-focused roles in brand management, cost management, and transition planning.